Korea’s RSA system is moving to become more of a performance-based mechanism rather than a finance-based system.

Performance-based RSA means that the system will be using real-world data (RWD) from clinical practice as real-world evidence (RWE). Ultra-high-priced drugs like Kymriah inj. (tisagenlecleucel) have had difficulties in reimbursement, and the government's RSA expansion attempt may be an important tool that can increase patient accessibility.

Ji-Hye Byun (Ph.D. in Social Pharmacy), Head of Evidence-based research at the Health Insurance Review & Assessment Service, presented on ‘Plans for reimbursement management in Korea, including pharmaceuticals using RWD, etc’ at